Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Vergenix STR
- Development stage
- Unknown
- Lead developer
- CollPlant Biotechnologies
- Modality
- Nanoparticles → Drug Delivery Systems, Recombinant Proteins and Enzymes, Hydrogel Systems → Drug Delivery Systems, Device-based Delivery → Drug Delivery Systems
- Administration
- Intra-lesional
01
Overview
Vergenix STR (Soft Tissue Repair Matrix) is a medical device developed by CollPlant Biotechnologies for the treatment of tendinopathy and other soft tissue injuries. It is an injectable gel composed of cross-linked recombinant human type I collagen (rhCollagen), produced using a proprietary plant-based expression system. At the point of care, the gel is mixed with autologous platelet-rich plasma (PRP) and injected into the injury site. The resulting collagen-fibrin matrix acts as a temporary scaffold that supports cell adhesion and proliferation while providing a reservoir for the sustained, localized release of growth factors from the PRP. This mechanism promotes tissue regeneration and accelerates the healing process in conditions such as tennis elbow (lateral epicondylitis), rotator cuff tears, and Achilles tendon injuries. The product is CE-marked for use in various tendinopathies.
- Brand names
- Vergenix STR
- Other names
- Vergenix STR Soft Tissue Repair Matrix
02
Targets
COL1 (Collagen type I)
Beyond the preview
Go deeper on Vergenix STR.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Vergenix STR.